Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
- Mehdi BananAffiliated withGenetics Research Center, University of Social Welfare and Rehabilitation Sciences Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hydroxyurea (HU) is a drug that induces fetal hemoglobin production. As a result, HU is widely used to treat β-thalassemia (β-thal) patients. However, the response of these patients to HU varies. Some β-thal patients respond favorably to treatment while others do not respond at all. HU has a number of side-effects and therefore its targeted prescription is beneficial. Hence, identifying the genetic determinants which lead to the differential HU response is important. This review summarizes recent findings which have shed light on this topic. Special emphasis is given to the mechanisms and genetic loci which may govern these differences. These findings have helped identify several single nucleotide polymorphisms which associate with the response to HU in both β-thal and sickle cell disease patients.
Keywordsβ-thalassemia Hydroxyurea Pharmacogenomics HbF
- Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
Annals of Hematology
Volume 92, Issue 3 , pp 289-299
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Mehdi Banan (1)
- Author Affiliations
- 1. Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Evin, Daneshjoo Blvd., Koodakyar St, Tehran, Iran